Glucotrol & Glucotrol XL
Indications
Glipizide is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Available as immediate-release Glucotrol (initial U.S. approval 1984) and extended-release Glucotrol XL (initial U.S. approval 1994), glipizide is a second-generation sulfonylurea that lowers blood glucose primarily by stimulating insulin secretion from pancreatic beta cells. The expected HbA1c reduction is approximately 1.0–1.5% as monotherapy — among the larger reductions of any oral antidiabetic class — which along with low cost and longstanding clinical experience explains its continued role despite the emergence of newer agents with better cardiovascular and weight profiles.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 2 diabetes — glycemic control | Adults (≥18 years) | Adjunct to diet and exercise; mono- or combination | FDA Approved |
| Combination with metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, or insulin | Adults inadequately controlled on monotherapy | Add-on therapy | FDA Approved |
| Conversion from immediate-release to extended-release | Adults stable on Glucotrol IR | Switch to nearest equivalent total daily dose of XL (max 20 mg/day) | FDA Approved |
| Conversion from insulin (T2DM with residual beta-cell function) | Adults on insulin who may be candidates for oral therapy | Insulin tapering with concurrent glipizide initiation | FDA Approved |
| Pediatric type 2 diabetes | Patients <18 years | — | Not Approved |
| Type 1 diabetes / diabetic ketoacidosis | — | — | Contraindicated |
Glipizide should not be used in patients with type 1 diabetes or diabetic ketoacidosis, both of which require insulin therapy. Within current treatment algorithms, the ADA Standards of Care position sulfonylureas as a lower-tier option behind metformin, GLP-1 receptor agonists, and SGLT2 inhibitors — particularly in patients with established cardiovascular disease, heart failure, or chronic kidney disease, where the latter classes provide organ-protective benefits that sulfonylureas do not. Sulfonylureas remain a reasonable choice when cost is the dominant consideration, when newer agents are unavailable or contraindicated, or when a brisk reduction in HbA1c is needed in the near term and weight gain or hypoglycemia risk is acceptable.
Pediatric T2DM (Evidence: Insufficient) — Safety and effectiveness in pediatric patients have not been established. Glipizide is not approved for use in patients younger than 18 years, and pediatric T2DM management generally favors metformin and GLP-1 receptor agonists.
Inpatient hyperglycemia (Evidence: Negative — Not Recommended) — Sulfonylureas are generally avoided in hospitalized patients due to fluctuating oral intake, variable renal/hepatic function, and risk of prolonged hypoglycemia. Insulin is preferred for inpatient glycemic management.
Cardiovascular benefit (Evidence: Negative) — No clinical study has established conclusive evidence of macrovascular risk reduction with glipizide or any antidiabetic drug other than GLP-1 receptor agonists and SGLT2 inhibitors. The CAROLINA trial vindicated cardiovascular safety of glimepiride versus linagliptin and is often extrapolated to support the safety of modern second-generation sulfonylureas — but glipizide itself has not been studied in a dedicated cardiovascular outcomes trial.
Dosing
Glipizide is available in two formulations with distinct administration requirements. Immediate-release Glucotrol should be taken approximately 30 minutes before breakfast or the first main meal of the day; this timing matches the drug’s rapid absorption profile to the post-prandial glucose rise. Extended-release Glucotrol XL uses a non-deformable osmotic-pump delivery system and must be swallowed whole with breakfast — never crushed, chewed, or split. The osmotic shell is biologically inert and is excreted intact in the stool; patients should be informed that seeing the empty tablet in the bowel movement is expected and not a sign of treatment failure.
| Clinical Scenario | Starting Dose | Titration | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — adult, IR (Glucotrol) | 5 mg PO once daily 30 min before breakfast | Increase by 2.5–5 mg every several days based on glycemic response | 40 mg/day total Maximum once-daily dose 15 mg; doses >15 mg given as BID before meals | Most patients controlled with 5–15 mg/day. Some patients respond better to divided dosing even at lower totals. |
| T2DM — adult, XL (Glucotrol XL) | 5 mg PO once daily With breakfast | Adjust based on glycemic control; doses >10 mg may not produce additional average HbA1c reduction | 20 mg/day | Swallow whole; do not crush, chew, or split. Tablet shell appears intact in stool. |
| Switching from IR to XL | Match nearest equivalent total daily dose; alternatively, restart at 5 mg XL once daily | 20 mg/day | No transition period required. | |
| Hepatic impairment (IR) | 2.5 mg PO once daily | Conservative titration; monitor closely for hypoglycemia | Individualized | Hepatic impairment may reduce metabolism and gluconeogenic capacity. XL not specifically studied in hepatic impairment — start cautiously or avoid. |
| Renal impairment | Conservative starting dose Glipizide is preferred among sulfonylureas in moderate CKD due to inactive metabolites | Slow titration with frequent monitoring | Individualized | Not formally studied across renal-function strata. Inactive metabolite half-life prolonged in severe renal impairment, but parent drug clearance is largely preserved. |
| Older adults (≥65 years), debilitated, malnourished | 2.5 mg PO once daily For both IR and XL | Slow, individualized titration | Individualized | Greater hypoglycemia risk; 1–2 days longer to reach steady state with XL. |
| Switching from insulin (≤20 units/day) | Discontinue insulin; initiate glipizide at standard starting dose | Per standard titration | Monitor SMBG several times daily during transition. | |
| Switching from insulin (>20 units/day) | Reduce insulin dose by 50%; initiate glipizide at standard dose; taper insulin gradually based on response | Per standard titration | Hospitalization may be advisable when insulin requirement exceeds 40 units/day. Test urine for sugar and ketones at least three times daily during transition. | |
| Concurrent CYP2C9 inhibitors (e.g., fluconazole) | Initiate at lowest practical dose; monitor closely for hypoglycemia | Conservative | Fluconazole increases glipizide AUC by ~57%. Seek alternatives where feasible. | |
| Concurrent colesevelam | Administer glipizide at least 4 hours before colesevelam | Colesevelam reduces glipizide AUC by 12% and Cmax by 13% when co-administered. | ||
| Missed dose | Take 30 minutes before the next meal; otherwise skip | Do not double dose. Monitor for hypoglycemia. | ||
The maximum doses for the two formulations are not the same. Immediate-release Glucotrol can be titrated up to 40 mg/day total (with single doses up to 15 mg, doses above that as BID), while extended-release Glucotrol XL has a maximum of 20 mg/day. When converting from IR to XL, this asymmetry must be respected: a patient stable on Glucotrol 20 mg twice daily (40 mg total) cannot be matched to a single XL dose because the maximum XL dose is half that. Consider reducing the prior IR daily total or maintaining the IR formulation if higher doses are required for control.
Within the sulfonylurea class, glipizide differs from glyburide by its shorter half-life (2–4 h vs ~10 h), inactive metabolites, and consequently lower risk of prolonged hypoglycemia in renal impairment. Glipizide and glimepiride are generally preferred over glyburide in older adults and in patients with reduced renal function. The 2023 American Geriatrics Society Beers Criteria continues to recommend avoidance of glyburide in older adults; glipizide and glimepiride are not on the avoid list, though hypoglycemia risk remains a class-wide concern. CAROLINA — the largest dedicated cardiovascular outcomes trial in the sulfonylurea class — evaluated glimepiride and demonstrated cardiovascular non-inferiority versus linagliptin; these findings are typically extrapolated to glipizide despite the absence of a dedicated trial.
Pharmacology
Mechanism of Action
Glipizide lowers blood glucose primarily by stimulating insulin release from pancreatic beta cells — an effect that is dependent on functioning beta cells and on the presence of glucose. The molecular target is the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium (KATP) channel on beta-cell membranes. Binding closes the channel, depolarizes the cell, opens voltage-gated calcium channels, and triggers exocytosis of pre-formed insulin granules. Because the insulinotropic effect is not glucose-dependent in the same way as the incretin-mediated mechanisms of GLP-1 receptor agonists or DPP-4 inhibitors, sulfonylureas can produce hypoglycemia even when blood glucose is normal — the principal class-defining safety concern.
Beyond its acute insulinotropic action, glipizide produces modest extra-pancreatic effects that are clinically minor. Glipizide has no antidiuretic activity and does not adversely affect plasma lipoproteins. The expected HbA1c reduction is approximately 1.0–1.5% as monotherapy, comparable to or greater than that of metformin and meaningfully larger than DPP-4 inhibitors. C-peptide responses remain enhanced after at least 6 months of treatment, indicating durable insulinotropic activity, though glycemic durability over years is generally inferior to metformin and to thiazolidinediones in head-to-head studies. Modest weight gain — approximately 1.2 kg over 52 weeks in the Bailey 2011 head-to-head trial versus dapagliflozin — is typical, contrasting unfavorably with the weight neutrality or weight loss seen with metformin, GLP-1 receptor agonists, and SGLT2 inhibitors.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption (IR) | Bioavailability 100%; Tmax 1–3 h; absorption delayed ~40 min by food (no effect on total absorption) | Take 30 min before meals to align peak effect with post-prandial glucose rise. |
| Absorption (XL) | Osmotic-pump delivery; 2–3 h lag time; Tmax 6–12 h; relative bioavailability ~90% vs IR; high-fat meal increases Cmax by 40% (no change in lag time or AUC) | Take with breakfast at the same time daily. Steady state reached by day 5 (1–2 days longer in older adults). |
| Distribution | Vd ~11 L (small, indicative of localization within the extracellular fluid compartment); plasma protein binding 98–99% (predominantly to albumin via non-ionic binding) | High protein binding limits free fraction. Dialysis is unlikely to remove glipizide effectively in overdose. |
| Metabolism | Extensive hepatic metabolism, primarily by CYP2C9 (with smaller CYP3A4 contribution); hepatic uptake mediated by OATP1B3; major metabolites (4-trans-hydroxyglipizide and others) are pharmacologically inactive | CYP2C9 polymorphisms (*2, *3) and OATP1B3 variants increase exposure and hypoglycemia risk in some patients. |
| Elimination | ~68% of an oral dose recovered in urine (primarily as inactive metabolites); approximately 11% in feces; <10% excreted unchanged in urine; elimination half-life 2–4 h (range 2–7.3 h); no accumulation with repeated dosing | Short half-life mitigates risk of prolonged hypoglycemia compared with longer-acting sulfonylureas. Inactive metabolite half-life can extend to >20 h in severe renal impairment, but metabolites are not pharmacologically active. |
Side Effects
The dominant adverse effect of glipizide is hypoglycemia, which can be severe, prolonged, or recurrent — particularly in older adults, those with renal or hepatic impairment, those with reduced caloric intake, and those receiving CYP2C9 inhibitors. In the original FDA approval studies, 11.8% of 702 patients reported any adverse reaction and only 1.5% required treatment discontinuation. Direct head-to-head data from the Bailey 2011 trial of glipizide versus dapagliflozin (52 weeks, n=814) showed any-hypoglycemia in 40.8% of glipizide-treated patients (vs 3.5% with dapagliflozin), establishing a useful real-world benchmark for cumulative glipizide-related hypoglycemia exposure.
| Adverse Effect | Rate / Pattern | Clinical Note |
|---|---|---|
| Hypoglycemia (any) with glipizide over 52 weeks (Bailey 2011) | 40.8% | Versus 3.5% with dapagliflozin add-on to metformin in the same trial. |
| Hypoglycemia (any) with glimepiride over 6.3 years (CAROLINA — class extrapolation) | 37.7% | Glimepiride-derived data; the closest large modern dataset for sulfonylurea-related hypoglycemia exposure. |
| Adverse Effect | Approximate Incidence | Clinical Note |
|---|---|---|
| Weight gain | +1.2 kg over 52 weeks (Bailey 2011) | Typical with insulin secretagogues. Compared with weight loss of −3.2 kg with dapagliflozin in the same trial. |
| Dizziness | >3% (FDA PI) | May overlap with mild hypoglycemia symptoms; assess SMBG before attributing to other causes. |
| Diarrhea | >3% (FDA PI) | Usually mild and self-limited. |
| Nervousness / tremor | >3% (FDA PI) | Frequently a manifestation of hypoglycemia rather than direct drug effect. |
| Flatulence | >3% (FDA PI) | Mild and typically transient. |
| Severe hypoglycemia (sulfonylurea class, long-term — CAROLINA glimepiride arm) | 2.2% over 6.3 years | Defined as event requiring assistance from another person. Risk is increased by drug interactions, renal impairment, and missed meals. |
| Allergic skin reactions (urticaria, pruritus, morbilliform rash) | <1.5% | Often transient; may resolve with continued use. Discontinue if persistent. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe / prolonged hypoglycemia | Cumulative risk rises with duration and comorbidity (CAROLINA glimepiride: 2.2% over 6.3 yr) | Days to years; recurrence possible 24–48 h after apparent recovery | IV 50% dextrose followed by continuous 10% dextrose infusion targeting BG >100 mg/dL; hospitalize and observe at least 24–48 h. |
| Hematologic disorders | Postmarketing (rare) | Variable | Discontinue and obtain hematology consultation. Includes leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia. |
| Cholestatic / hepatocellular jaundice | Postmarketing (rare) | Weeks to months | Discontinue at first sign of jaundice or marked LFT elevation. Most cases resolve. |
| Hyponatremia / SIADH | Postmarketing (rare); class effect | Variable | Less common with glipizide than with first-generation chlorpropamide. Investigate new-onset hyponatremia in any sulfonylurea-treated patient. |
| Severe hypersensitivity (anaphylaxis, angioedema, SJS, exfoliative dermatitis, photosensitivity) | Postmarketing (rare) | Days to weeks | Discontinue permanently; emergency care; absolute contraindication to re-challenge. |
| Cardiovascular events (UGDP-derived class warning) | Historical; current relevance debated | Long-term | FDA-mandated warning carried over from the 1970 UGDP study of tolbutamide. CAROLINA (glimepiride vs linagliptin) supports cardiovascular safety of modern sulfonylureas, but the labeling warning remains in place. |
| Sulfonamide cross-reactivity | Theoretical / case-based | First exposure | Caution in patients with documented severe sulfonamide allergy. Cross-reactivity is uncommon but reported. |
| Hepatic porphyria / disulfiram-like reactions | Postmarketing (rare); reported with sulfonylureas | Variable | Per FDA labeling, glipizide pretreatment did not cause acetaldehyde accumulation in mouse studies, but rare clinical reports exist. |
| Reason for Discontinuation | Pattern | Context |
|---|---|---|
| Hypoglycemia (frequent or severe) | Common over time | Often resolved by dose reduction; switch to non-secretagogue if recurrent. |
| Secondary failure (loss of efficacy) | Common over years | Reflects natural progression of T2DM. Most patients eventually require add-on therapy or transition to insulin. |
| Weight gain | Variable | May prompt switch to weight-neutral or weight-lowering agents. |
| Allergic skin reactions | <1.5% | Discontinue if persistent; class re-challenge possible after careful evaluation if mild. |
| GI intolerance | Uncommon | Often improves over time or with dose adjustment. |
Severe hypoglycemia from glipizide is a medical emergency requiring immediate intravenous concentrated glucose (50% dextrose) followed by a continuous 10% dextrose infusion sufficient to maintain blood glucose above 100 mg/dL. Hospitalize and observe for at least 24 to 48 hours — recurrence is well-documented after apparent clinical recovery, particularly with extended-release glipizide and in patients with renal impairment. Because of high (98–99%) plasma protein binding, hemodialysis is unlikely to be effective for overdose management. Octreotide may be considered as adjunctive therapy in refractory or recurrent sulfonylurea-induced hypoglycemia by suppressing glucose-stimulated insulin release.
Drug Interactions
Glipizide is metabolized primarily by CYP2C9 with hepatic uptake by OATP1B3, creating multiple opportunities for clinically meaningful drug interactions. The two practical interaction categories are pharmacokinetic — increased glipizide exposure leading to hypoglycemia (CYP2C9 inhibitors, OATP1B3 inhibitors) and pharmacodynamic — additive hypoglycemic effect (insulin, other antidiabetic agents, ethanol). Several less obvious drugs also reduce glipizide effectiveness through enzyme induction or altered absorption.
Monitoring
Glipizide monitoring centers on glycemic response, hypoglycemia surveillance, and assessment of hepatic and renal function (which influences exposure and recovery from hypoglycemia). Self-monitored blood glucose or continuous glucose monitoring is particularly important in older adults, those with renal impairment, and those receiving CYP2C9 inhibitors. Routine hematologic monitoring is not required but should be considered at clinical signs (unexplained bruising, infection, fatigue).
-
HbA1c
Every 3 months until at goal, then every 6 months
Routine Expected reduction approximately 1.0–1.5% over 3 months. Lack of expected response after adequate titration suggests secondary failure or non-adherence. -
Fasting Plasma Glucose
As clinically indicated; FDA labeling recommends at least 2 consecutive similar values 7 days apart before titration
Routine Useful for short-term titration decisions, particularly in the first weeks of therapy or after dose adjustments. -
Self-Monitored or CGM
Daily during titration; periodic thereafter
Routine Critical during initiation, dose escalation, and addition of any drug that may affect glycemic control. Older adults benefit from CGM where available. -
Hypoglycemia Symptoms
Every visit; immediate review with new symptoms
Trigger-based Specifically inquire about unexplained dizziness, sweating, tremor, palpitations, or confusion — particularly nocturnal episodes. Beta-blocker users may lose adrenergic warning signs and experience neuroglycopenia first. -
Body Weight
Each visit
Routine Modest weight gain (~1.2 kg over 52 weeks in head-to-head trial data) is typical. Significant gain may prompt reassessment, particularly in patients with obesity or cardiovascular disease. -
Renal Function (eGFR)
At baseline; annually thereafter
Routine Worsening renal function increases exposure to glipizide metabolites and prolongs hypoglycemia risk. Consider dose reduction or class switch in advancing CKD. -
Liver Function (AST, ALT, alkaline phosphatase)
At baseline and as clinically indicated
Trigger-based Mild-to-moderate elevations of ALT, LDH, alkaline phosphatase, BUN, and creatinine have been noted but causality is uncertain. New jaundice or marked LFT elevation warrants discontinuation. -
Complete Blood Count
Symptom-driven
Trigger-based Routine surveillance not required. Investigate unexplained infection, bruising, or fatigue with CBC; rare cases of pancytopenia and other cytopenias have been reported. -
Serum Sodium
Symptom-driven
Trigger-based Hyponatremia and SIADH have been reported as a sulfonylurea class effect, though less commonly with glipizide than chlorpropamide. Investigate new neurological symptoms or volume changes. -
Lipid Panel & BP
Per general CV risk management guidelines
Routine Glipizide does not adversely affect lipoprotein profile or blood pressure directly. Standard CV risk surveillance still applies.
Contraindications & Cautions
The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality compared to treatment with diet alone or diet plus insulin, based on the University Group Diabetes Program (UGDP) study published in 1970. Although the UGDP study evaluated tolbutamide specifically, the FDA has applied this warning to all sulfonylureas based on shared pharmacology. Despite ongoing controversy surrounding the UGDP results — and despite reassuring contemporary evidence from the CAROLINA trial of glimepiride — the warning remains in current FDA labeling for all sulfonylureas, including glipizide. Patients should be informed of the potential cardiovascular risks and the availability of alternative therapies.
Absolute Contraindications
- Known hypersensitivity to glipizide or any component of the formulation.
- Type 1 diabetes mellitus — sulfonylureas require functioning beta cells and are not effective.
- Diabetic ketoacidosis with or without coma — insulin is the cornerstone of treatment.
Relative Contraindications (Specialist Input Recommended)
- Severe sulfonamide hypersensitivity — cross-reactivity with sulfonylureas is uncommon but reported. Avoid in patients with documented severe sulfonamide reactions.
- Severe renal impairment (CrCl <30 mL/min) — formal data are limited. Inactive metabolite half-life is prolonged but pharmacologically inactive; nevertheless, hypoglycemia risk is increased and dose reduction is prudent.
- Severe hepatic impairment — reduced metabolism plus diminished gluconeogenic capacity raise hypoglycemia risk substantially. Glucotrol XL has not been specifically studied in hepatic impairment.
- Pregnancy — insulin is the preferred therapy. If glipizide is continued, it should be discontinued at least 2 weeks before the expected delivery date because of the risk of severe neonatal hypoglycemia, which has been reported to last up to 4–10 days after birth.
- G6PD deficiency — sulfonamide-derived drugs as a broad class can rarely precipitate hemolytic anemia in this population; case reports with sulfonylureas are uncommon but use with caution.
Use with Caution
- Older adults, debilitated, or malnourished patients — heightened hypoglycemia risk; start with 2.5 mg (IR or XL).
- Adrenal or pituitary insufficiency — impaired counter-regulatory response increases hypoglycemia severity.
- Cardiovascular disease — UGDP-derived warning remains in labeling; consider GLP-1 RA or SGLT2 inhibitor first-line if appropriate.
- Concurrent CYP2C9 inhibitors (fluconazole, miconazole, amiodarone) — start at lowest practical dose with intensified glucose monitoring.
- Concurrent ethanol use — counsel against binge drinking and drinking on an empty stomach.
- Driving or operating heavy machinery — hypoglycemia can impair concentration and reaction time. Ensure stable glycemic control before resuming such activities, particularly during titration.
- Acute illness, surgery, or interrupted oral intake — temporarily hold glipizide and substitute insulin if needed; resume only after re-establishment of normal nutrition.
- Breastfeeding — limited human data; some sulfonylureas are excreted in breast milk. Decide between continuing the drug and continuing breastfeeding based on individual circumstances.
Patient Counselling
Purpose of Therapy
Explain that glipizide helps the pancreas release more insulin to lower blood sugar, complementing diet, exercise, and weight management. It typically lowers HbA1c by about 1 to 1.5 percentage points and is well-established and inexpensive. The two main side effects to be aware of are low blood sugar (particularly if meals are missed or alcohol is consumed on an empty stomach) and modest weight gain. The medication does not improve heart attack or kidney outcomes the way some newer diabetes medications do — those classes (GLP-1 receptor agonists and SGLT2 inhibitors) may be considered if these benefits are a treatment goal.
How to Take
Glucotrol (immediate-release): Take approximately 30 minutes before breakfast at the same time every day. If a higher dose has been prescribed (more than 15 mg per day), it will typically be split into two doses, one before breakfast and one before the evening meal.
Glucotrol XL (extended-release): Take with breakfast at the same time every day. Swallow the tablet whole — do not crush, chew, split, or break it. The tablet shell is a non-absorbable plastic-like material that releases the medication slowly through tiny laser-drilled openings; the empty shell will appear in the stool after the medicine has been released. This is normal and does not mean the medicine is not working.
If a dose is missed, take it 30 minutes before the next meal. If the next dose is almost due, skip the missed dose and resume the regular schedule — do not double up. Store at room temperature (20–25°C / 68–77°F), away from moisture and humidity. Keep out of reach of children.
Sources
- U.S. Food and Drug Administration. Glucotrol XL (glipizide) extended release tablets prescribing information. Pfizer/Roerig; revised 2021. accessdata.fda.gov Definitive U.S. labeling for the extended-release formulation — primary source for dosing (5 mg starting dose with breakfast, 20 mg/day maximum), pharmacokinetics (osmotic-pump mechanism, 6–12 h Tmax, 90% relative bioavailability), and the fluconazole and colesevelam interaction data.
- U.S. Food and Drug Administration. Glucotrol (glipizide) tablets prescribing information. Pfizer/Roerig. accessdata.fda.gov Reference labeling for immediate-release glipizide — covers the 30-minute pre-meal administration, 5 mg starting dose, 40 mg/day maximum (15 mg single-dose ceiling, BID for higher totals), 11 L apparent volume of distribution, and 98–99% protein binding.
- National Library of Medicine, DailyMed. Glucotrol XL (glipizide) extended release tablets. dailymed.nlm.nih.gov Continuously updated full prescribing information; useful for cross-checking the most current label changes.
- University Group Diabetes Program (UGDP). A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19(Suppl 2):747–830. The historical study of tolbutamide that produced the FDA-mandated cardiovascular mortality warning that remains on all sulfonylurea labels, including glipizide. Methodology and conclusions have been debated for decades.
- Rosenstock J, Kahn SE, Johansen OE, et al; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–1166. doi.org/10.1001/jama.2019.13772 The largest dedicated cardiovascular outcomes trial of any sulfonylurea (n=6,033, median 6.3 yr). 3P-MACE HR 0.98 (95.47% CI 0.84–1.14) for linagliptin vs glimepiride; any-hypoglycemia 37.7% on glimepiride; severe hypoglycemia 2.2%. Provides modern reassurance regarding sulfonylurea cardiovascular safety, typically extrapolated to glipizide.
- Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. Diabetes Care. 2011;34(9):2015–2022. Companion paper to the dapagliflozin vs glipizide trial. doi.org/10.2337/dc11-0606 Head-to-head 52-week trial of dapagliflozin vs glipizide added to metformin (n=814) showing equivalent HbA1c reduction (−0.52% in both arms) but markedly higher hypoglycemia (40.8% vs 3.5%) and weight gain (+1.2 kg vs −3.2 kg) with glipizide. Directly informs the modern glipizide adverse-effect benchmark.
- Hirst JA, Farmer AJ, Dyar A, Lung TWC, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56(5):973–984. doi.org/10.1007/s00125-013-2856-6 Systematic review establishing the ~1.5% HbA1c reduction with sulfonylurea monotherapy and ~1.6% in combination, supporting the efficacy benchmark used in this monograph.
- Lebovitz HE. Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use. Pharmacotherapy. 1985;5(2):63–77. PMID 3923454 Foundational pharmacology and clinical-use review at the time of FDA approval.
- American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes. Diabetes Care. Updated annually. diabetesjournals.org/care Authoritative U.S. guidance; positions sulfonylureas as a lower-tier option behind metformin, GLP-1 receptor agonists, and SGLT2 inhibitors, with cost as the primary advantage.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi.org/10.2337/dci22-0034 ADA-EASD consensus shaping the relative role of sulfonylureas versus newer classes; positions sulfonylureas as a cost-driven option when other agents are unsuitable.
- 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi.org/10.1111/jgs.18372 Recommends avoidance of glyburide in older adults due to prolonged hypoglycemia risk; glipizide and glimepiride are not on the avoid list but require careful use.
- Yang F, Liu L, Chen L, et al. OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. Sci Rep. 2018;8(1):18063. doi.org/10.1038/s41598-018-36212-7 Defines the OATP1B3-mediated hepatic uptake and CYP2C9 metabolism of glipizide and the impact of common pharmacogenomic variants on exposure and hypoglycemia risk.
- Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia. 1973;9(Suppl 1):331–338. doi.org/10.1007/BF01218443 Foundational human pharmacokinetic study; demonstrated 100% oral bioavailability, ~3.7 h half-life, and prolongation of metabolite half-life (but not parent drug) in renal insufficiency. 68% urinary excretion documented.
- National Center for Biotechnology Information. Glipizide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. ncbi.nlm.nih.gov/books/NBK459177 Continuously updated open-access reference summarizing current evidence on mechanism, pharmacokinetics, dosing, and adverse effects.